Hemostemix Announces First Patient Treated in Phase II Clinical Trial
03. Mai 2018 08:30 ET
|
Hemostemix Inc.
CALGARY, Alberta, May 03, 2018 (GLOBE NEWSWIRE) -- Hemostemix Inc. (“Hemostemix” or the “Company”) (TSX VENTURE:HEM) is pleased to announce that it has treated its first patient under its continuing...
Hemostemix Announces Trial Site for Phase II Clinical Trial
27. April 2018 08:30 ET
|
Hemostemix Inc.
CALGARY, Alberta, April 27, 2018 (GLOBE NEWSWIRE) -- Hemostemix Inc. (“Hemostemix” or the “Company”) (TSX VENTURE:HEM) is pleased to announce that it has entered into an agreement and has received...
Hemostemix Announces US FDA Clinical Trial Approval
19. April 2018 08:30 ET
|
Hemostemix Inc.
NOT FOR DISSEMINATON TO U.S. WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES CALGARY, Alberta, April 19, 2018 (GLOBE NEWSWIRE) -- Hemostemix Inc. (“Hemostemix” or the “Company”) (TSX...
Hemostemix Signs License Agreement with Aspire Health Science
26. Februar 2018 08:00 ET
|
Hemostemix Inc.
CALGARY, Alberta, Feb. 26, 2018 (GLOBE NEWSWIRE) -- Hemostemix Inc. (“Hemostemix” or the “Company”) (TSX VENTURE:HEM) is pleased to announce it has finalized the terms of a license agreement (the...
Hemostemix Signs License Agreement with Aspire Health Science
23. Februar 2018 08:00 ET
|
Hemostemix Inc.
NOT FOR DISSEMINATION TO U.S. WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES CALGARY, Alberta, Feb. 23, 2018 (GLOBE NEWSWIRE) -- Hemostemix Inc. (“Hemostemix” or the “Company”) (TSX...
Hemostemix Signs Manufacturing Agreement with Aspire Health Science
22. Februar 2018 08:00 ET
|
Hemostemix Inc.
CALGARY, Alberta, Feb. 22, 2018 (GLOBE NEWSWIRE) -- Hemostemix Inc. (“Hemostemix” or the “Company”) (TSX VENTURE:HEM) is pleased to announce it has finalized the terms of a contract manufacturing...
Hemostemix Receives Health Canada Clearance to Continue with Critical Limb Ischemia Clinical Trials
20. Dezember 2017 07:30 ET
|
Hemostemix Inc.
CALGARY, Alberta, Dec. 20, 2017 (GLOBE NEWSWIRE) -- Hemostemix Inc. (“Hemostemix” or the “Company”) (TSX VENTURE:HEM) announced today that they have received a No Objection Letter from Health Canada...
Hemostemix Drives Forward with Talented New Management into New Headquarters
30. November 2017 11:17 ET
|
Hemostemix Inc.
NOT FOR DISSEMINATION TO U.S. WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES CALGARY, Alberta, Nov. 30, 2017 (GLOBE NEWSWIRE) -- Hemostemix Inc. (“Hemostemix” or the “Company”) (TSX...
Hemostemix Announces Agreement with CRO Service Provider Topstone Research
26. September 2017 08:00 ET
|
Hemostemix Inc.
BLACKFALDS, Alberta, Sept. 26, 2017 (GLOBE NEWSWIRE) -- Hemostemix Inc. (“Hemostemix” or the “Company”) (TSX VENTURE:HEM) is pleased to announce it has engaged Topstone Research Inc. (“Topstone”) to...
Hemostemix Completes Conversion of Subscription Receipts and Secured Credit Financing
15. September 2017 18:55 ET
|
Hemostemix Inc.
NOT FOR DISSEMINATION TO U.S. WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES BLACKFALDS, Alberta, Sept. 15, 2017 (GLOBE NEWSWIRE) -- Hemostemix Inc. (“Hemostemix” or the “Company”) (TSX...